A Study of Patients Receiving Adjuvant Nivolumab Therapy for Melanoma That Has Been Removed

Korábbi kezelés

• Any patient with a diagnosis of persisting advanced melanoma prior to first administration of nivolumab
• Any patient currently enrolled in an interventional clinical trial for his/her melanoma treatment (note: patients who have completed their participation in an interventional trial or who are no longer receiving the study drug and are only followed up for Overall Survival (OS)/ Relapse Free Survival (RFS) can be enrolled. In case of a blinded study, the treatment arm needs to be known).
  • Other protocol defined inclusion/exclusion criteria could apply

• Patients with a primary diagnosis of melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection and have no evidence of disease.
• Decision to treat with adjuvant nivolumab therapy has already been taken
• At least 18 years of age at the time of treatment decision
• Patients who provide written informed consent to participate in the study (for retrospectively enrolled patients who are deceased at time of study start, a consent waiver will be sought)